AVAC Report 2014/15: Prevention on the Line [Executive Summary]

This executive summary, excerpted from AVAC Report 2014/15, puts the current discussion about global targets for ending AIDS in context. What makes a good target? What targets have worked in the past—and why? What is the state of HIV prevention targets and plans today?

Essential Actions for HIV Prevention Research Rollout 2014/15

This updated version of AVAC’s 3D graphic shows priorities across the research-to-rollout spectrum. The graphic appears in AVAC Report 2014/15: Prevention on the Line.

What do women want in multipurpose technologies?

Multipurpose Prevention Technologies (MPTs) are a fast-growing area in women’s sexual and reproductive health. On November 12, AVAC and CAMI Health co-hosted a webinar: MPT Acceptability in Uganda, Nigeria and South Africa.

PrEP by the Numbers: Efficacy, regulatory approval and more

PrEP works if you take it. The figures on this graphic show the relationship between PrEP efficacy and adherence and the status of regulatory action on PrEP worldwide. It also shows other potential new formulations of ARV-based prevention being evaluated as additional options in the future.

The Tipping Point: Moving From Rhetoric to Real Milestones for Ending AIDS

One way to measure progress in fighting AIDS is to compare the number of new HIV infections with the increase in HIV positive people on antiretroviral therapy (ART) over a given time period. An AIDS epidemic reaches its “tipping point” when the number of annual new HIV infection falls below the annual increase in patients starting ART. This poster was presented at the 2014 HIV Research for Prevention Conference in South Africa.

Resource Tracking to Ensure Accountability and Sustainability: HIV Prevention, Treatment U=U, Diagnostics and Cure Research Investment Analysis

This infographic explains how AVAC tracks HIV expenditures and investments. This has resulted in accurate and consistent year-to-year comparisons of grants and investment figures. This poster was presented at the 2014 HIV Research for Prevention (R4P) conference in South Africa.

Progress in VMMC Scale-up in Priority Countries

This map shows progress made through 2013 towards the target of circumcising 80% of eligible men in 14 priority countries. It is particularly useful as a tool for advocates to show how their country’s VMMC program compares to others in East and Southern Africa.

Global Investment in HIV Cure Research and Development in 2013

The International AIDS Society HIV Cure Resource Tracking group joined with the HIV Vaccines and Microbicides Tracking Working Group to estimate global investments in HIV cure research and produce this short report.

HIV Prevention Research & Development Investment in 2013: In a changing global development, economic and human rights landscape

This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The report shows that investment in HIV prevention research fell 4 percent in 2013, due to a combination of factors including declining investments by the United States and European donors, changes in the international development landscape and changes in the pipeline of HIV prevention products being tested.

When do you stop an HIV prevention trial for futility? A primer for HIV prevention advocates

This fact sheet looks at why trials are stopped early for “futility.” What does this mean, when is such a recommendation made and how does it affect other ongoing trials?